The HemOnc Pulse Editor's Special Episode: Future Directions in MPN Treatment with Dr. Hobbs
Oct 1, 2025
Dr. Gabriela Hobbs, a leading hematologist and MPN researcher at Massachusetts General Hospital, shares groundbreaking insights on myeloproliferative neoplasms. She delves into the impressive results from the VERIFY trial on rusfertide, detailing its hematocrit control and safety profile. Dr. Hobbs also discusses the efficacy of ropeginterferon and its advantages over traditional treatments. Additionally, she highlights ongoing clinical trials to watch and emphasizes the pressing need for therapies addressing thrombocytopenia and disease progression.
AI Snips
Chapters
Transcript
Episode notes
Imetelstat Plus Ruxolitinib Shows Tolerable Safety
- The IMPROVE-MF phase 1/1b shows imetelstat plus ruxolitinib is tolerable with expected cytopenias and no DLTs reported.
- Dose finding identified an RP2D to allow phase 1b efficacy evaluation of the combination.
BET Inhibitor Shows Multi-Domain Activity
- The BET inhibitor INC-B057643 showed expected class toxicities, mainly cytopenias, with some spleen and symptom responses.
- Early signals include anemia improvement and potential activity both as monotherapy and with ruxolitinib.
Ropeginterferon Outperforms Anagrelide In ET
- Ropeginterferon outperformed anagrelide in SURPASS-ET for blood count control, symptom improvement, and JAK2 allele burden reduction.
- It was better tolerated and lowered mutant allele burden across JAK2 and CALR subgroups seen so far.